These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31256288)

  • 21. Diffuse occipital hypometabolism on [18 F]-FDG PET scans in patients with idiopathic REM sleep behavior disorder: prodromal dementia with Lewy bodies?
    Fujishiro H; Iseki E; Murayama N; Yamamoto R; Higashi S; Kasanuki K; Suzuki M; Arai H; Sato K
    Psychogeriatrics; 2010 Sep; 10(3):144-52. PubMed ID: 20860570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of positron emission tomography imaging in movement disorders.
    Bohnen NI; Frey KA
    Neuroimaging Clin N Am; 2003 Nov; 13(4):791-803. PubMed ID: 15024962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease.
    Rus T; Schindlbeck KA; Tang CC; Vo A; Dhawan V; Trošt M; Eidelberg D
    Mov Disord; 2022 Nov; 37(11):2247-2256. PubMed ID: 36054380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD.
    Arnaldi D; Morbelli S; Brugnolo A; Girtler N; Picco A; Ferrara M; Accardo J; Buschiazzo A; de Carli F; Pagani M; Nobili F
    Parkinsonism Relat Disord; 2016 Aug; 29():47-53. PubMed ID: 27264343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
    Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
    J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes.
    Emsen B; Villafane G; David JP; Evangelista E; Chalaye J; Lerman L; Authier FJ; Gracies JM; Itti E
    Medicine (Baltimore); 2020 Nov; 99(45):e23060. PubMed ID: 33157962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].
    Arahata Y; Kato T; Tadokoro M; Sobue G
    Nihon Rinsho; 1997 Jan; 55(1):222-6. PubMed ID: 9014454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.
    Thobois S; Prange S; Scheiber C; Broussolle E
    Parkinsonism Relat Disord; 2019 Feb; 59():93-100. PubMed ID: 30181086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
    Juh R; Kim J; Moon D; Choe B; Suh T
    Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson's disease].
    Homenko JG; Susin DS; Kataeva GV; Irishina JA; Zavolokov IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):46-51. PubMed ID: 28638030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occipital hypometabolism is a risk factor for conversion to Parkinson's disease in isolated REM sleep behaviour disorder.
    Carli G; Meles SK; Janzen A; Sittig E; Kogan RV; Perani D; Oertel WH; Leenders KL;
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3290-3301. PubMed ID: 37310428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging.
    Teune LK; Renken RJ; de Jong BM; Willemsen AT; van Osch MJ; Roerdink JB; Dierckx RA; Leenders KL
    Neuroimage Clin; 2014; 5():240-4. PubMed ID: 25068113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease.
    Pilotto A; Premi E; Paola Caminiti S; Presotto L; Turrone R; Alberici A; Paghera B; Borroni B; Padovani A; Perani D
    Neurology; 2018 Mar; 90(12):e1029-e1037. PubMed ID: 29453242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism.
    Feigin A; Antonini A; Fukuda M; De Notaris R; Benti R; Pezzoli G; Mentis MJ; Moeller JR; Eidelberg D
    Mov Disord; 2002 Nov; 17(6):1265-70. PubMed ID: 12465066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron emission tomography imaging of regional cerebral glucose metabolism.
    Alavi A; Dann R; Chawluk J; Alavi J; Kushner M; Reivich M
    Semin Nucl Med; 1986 Jan; 16(1):2-34. PubMed ID: 2935938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
    Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
    Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restorative Strategies in Movement Disorders: the Contribution of Imaging.
    Lao-Kaim NP; Piccini P; Tai YF
    Curr Neurol Neurosci Rep; 2017 Nov; 17(12):98. PubMed ID: 29094222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.
    Matthews DC; Lerman H; Lukic A; Andrews RD; Mirelman A; Wernick MN; Giladi N; Strother SC; Evans KC; Cedarbaum JM; Even-Sapir E
    Neuroimage Clin; 2018; 20():572-579. PubMed ID: 30186761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.
    Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T;
    Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement.
    Derlin T; Afzal W; Wilke F; Apostolova I; Klutmann S; Meyer PT; Buhmann C; Hesse S; Buchert R
    Nuklearmedizin; 2010; 49(4):139-47. PubMed ID: 20502846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.